[{"indications": "Indications\u00a0treatment of acute migraine", "name": "RIZATRIPTAN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.7 Analgesics", "4.7.4 Antimigraine drugs", "4.7.4.1 Treatment of acute migraine", "5HT1-receptor agonists"], "cautions": "Cautions\u00a0see under 5HT1-receptor agonists above; interactions: Appendix 1 (5HT1 agonists)Driving\u00a0Drowsiness may affect performance\r\nof skilled tasks (e.g. driving)", "side-effects": "Side-effects\u00a0see under 5HT1-receptor\r\nagonists above; drowsiness, palpitation, tachycardia, dry mouth,\r\ndiarrhoea, dyspepsia, thirst, pharyngeal discomfort, dyspnoea, headache,\r\nparaesthesia, decreased alertness, insomnia, tremor, ataxia, nervousness,\r\nvertigo, confusion, myalgia and muscle weakness, sweating, urticaria,\r\npruritus, blurred vision; rarely syncope, hypertension,\r\ntoxic epidermal necrolysis; seizures and taste disturbance reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/73593.htm", "doses": ["10\u00a0mg as soon as possible after onset repeated after 2\r\nhours if migraine recurs (patient not responding should not take second\r\ndose for same attack); max. 20\u00a0mg in 24 hours; child and adolescent under 18 years not\r\nrecommended"], "pregnancy": "Pregnancy\u00a0\n(From 5HT1-receptor agonists: British National Formulary)\nPregnancy\u00a0There is limited experience of using 5HT1-receptor agonists during pregnancy; manufacturers advise that they should be avoided unless the potential benefit outweighs the risk."}]